Novo Nordisk, Sanofi, and Eli Lilly Lead in the $12 Billion U.S. Diabetes Monitoring, Treatment, and Drug Delivery Market,

Novo Nordisk, Sanofi, and Eli Lilly Lead in the $12 Billion U.S. Diabetes
Monitoring, Treatment, and Drug Delivery Market, Reports iData Research Inc.

As diabetes rates reach alarming rates in the United States, affecting close
to 10% of the total population, the market for diagnostics and treatment of
the illness grows.

VANCOUVER, Canada, July 15, 2013 (GLOBE NEWSWIRE) -- via PRWEB - According to
the latest statistics recorded by the American Diabetes Association, over 25
million children and adults in the United States were suffering from diabetes
in 2011. Moreover, it is estimated that there are 79 million people who are
prediabetic. People with prediabetes have an increased risk of becoming
diabetic and are susceptible to the complications associated with the disease.
However, if patients take action to better manage their blood glucose, they
can delay or prevent diabetes from developing. The illness is the seventh
leading cause of death in the U.S. and contributes to other maladies such as
heart disease, stroke, blindness, amputations, and kidney failure.

According to the latest intelligence from iData Research, the market for
diabetes monitoring, diagnosis, treatment, and drug delivery is valued at
nearly $12 billion. With its success in treating both type 1 and type 2
diabetes, insulin represents the largest portion of the market. "This market
is expected to maintain strong growth, and will be spurred by factors such as
the number of diabetics, obesities, and alternative modes of delivery, such as
insulin pens, pumps, and patches," explains Dr. Kamran Zamanian, CEO of iData
Research. "Units of insulin pens, for example, are expected to grow at
double-digit rates, as newly diagnosed diabetics who are prescribed insulin
are better informed of the conveniences of an insulin pen." The dominant pen
manufacturers are investing heavily in marketing, and the promotional backing
is proving to be a very strong market driver.

Due to its great presence in both the insulin and insulin pen market in the
U.S., Novo Nordisk is the market leader, dominating close to a quarter of the
total market with products such as the NovoLog® and Novolin®R insulin
products, and FlexPen®, NovoPen®, and NovoLet® insulin pens. Sanofi and Eli
Lilly occupy the second and third places in the total market, respectively,
competing with Novo Nordisk in the insulin and insulin pen markets. Lifescan
and Roche Diagnostics are also large players, working primarily in the
diabetes diagnostics sector. Lifescan is very involved in the diabetes
community and is working to improve patient education and patient quality of
life through development of new drugs, supporting legislation and healthcare
reform to benefit people with diabetes. Roche Diagnostics is focused on
innovation and forward-thinking solutions for healthcare. Their comprehensive
portfolio includes products for reference labs, hospital labs, blood banks and
specialty testing.

The global series on the Markets for Diabetes Monitoring, Treatment, and Drug
Delivery covering the U.S. and 15 counties in Europe is available here. The
full reports provide a comprehensive analysis including procedure numbers,
units sold, market value, forecasts, as well as a detailed competitive market
shares and analysis of major players' success strategies in each market and
segment. The reports also cover markets for: traditional blood glucose meters,
continuous glucose monitoring, blood glucose test strips, lancet and lancing
devices, insulin, insulin syringes, insulin pens, insulin pumps, as well as
emerging markets and alternative therapies.

About iData Research

iData Research is an international market research and consulting group
focused on providing market intelligence for medical device and pharmaceutical
companies. iData covers research in: diabetes, cardiac surgery, vascular
access, infusion therapy, cardiac rhythm management, patient monitoring, and
electronic medical records.

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit

CONTACT: iData Research
         Paula Olsen
Press spacebar to pause and continue. Press esc to stop.